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Geriatric individuals often exhibit an increased sensitivity or 
altered response to medications, due to several factors. Pharmaco-
dynamic changes or modification in the pharmacokinetic properties of 
the agent, which result from the physiologic changes associated with 
increasing age, frequently result in variance from common manifesta-
tions of pharmacologic action. Conversely, documented changes in 
pharmacokinetic parameters of drugs administered to elders may not 
always produce a clinically significant and observable change. 
As discussed by Bender, certain physiologic changes in the 
gastrointestinal tract may theoretically affect absorption of drugs.^  
Changes include achlorhydria, elevated gastric pH, decreased intes-
tinal blood flow and reduced gastrointestinal motility. Active and 
2 
passive absorption processes are impaired as well. The clinical 
significance resulting from changes in absorption has not been well 
demonstrated. 
Physiologic changes may also affect the distribution of a drug 
in the elderly. Age related differences are noted in body composi-
tion, including a diminished percent of total body water and muscle 
3 
mass, with a concomitant increase in proportion of body fat. 
4 
Changes in plasma protein concentrations, with less albumin, yet 
more alpha-l-acid glycoprotein5 and globulins have been reported. 
Changes in regional blood flow may affect the tissue permeability of 
an administered agent. These effects may alter the distribution of 
lipophilic or highly protein bound drugs, or lead to preferential 
distribution to certain tissues, resulting in accumulation and 
enhanced pharmacologic effect at that site. 
2 
Alterations in the metabolism of drugs are also incident to 
these physiologic changes. Although not well documented in human 
beings, investigation with animal models suggests a decline in liver 
6 
microsomal enzyme activity with age. However, a progressive decline 
7 8 in liver mass and hepatic blood flow from young adulthood to old 
age has been demonstrated in human subjects. However, recent 
evidence suggests there is no decline in cardiac output as a function 
9 
of aging. This may in turn be manifested as no change in hepatic 
blood flow. 
A decrease in the glomerular filtration rate, as measured by 
standard true twenty-four hour creatinine clearance, has also been 
10 
observed. In addition to a cross-sectional assessment, longitu-
dinal studies suggest that the rate of decline in renal function 
accelerates with increasing age. For drugs or active metabolites 
which undergo renal elimination, this physiologic change may be 
manifested as deviance from pharmacokinetic "norms" for elimination 
in younger individuals. 
The above noted physiologic changes associated with age, with 
the concomitant changes in the pharmacokinetic variables of absorp-
tion, distribution, metabolism and excretion of drugs, result in 
variable effects. Depending on the agent administered, clinically 
significant manifestations may or may not be observed. 
Evidence for changes in receptors and intracellular physiology, 
although not abundant, suggests that a pharmacodynamic change may 
occur without concomitant changes in pharmacokinetics. This may 
occur as an increased sensitivity to certain agents, primarily those 
11,12 
with central nervous system action such as the benzodiazepines 
3 
13 
and the tricyclic antidepressants. However, relative resistance to 
drug administration has also been observed, notably cardiac effects 
subsequent to propranolol and isoproterenol administration. 
As reviewed by Ouslander, many medications have been reported to 
exhibit altered pharmacokinetic or pharmacodynamic patterns when 
2 
administered to elderly individuals. Of special consideration are 
the narcotic analgesic agents, in that differences have been reported 15—17 18 19 20 for morphine, meperidine, fentanyl and alfentanil . 
Conversely, no change has been noted for propoxyphene, a synthetic 
21 
analgesic with structural similarities to other opiates. In an 
efficacy study, It was observed that morphine provided an increased 
and longer duration of pain relief after intramuscular administration 
to elderly post-operative cancer patients when compared to younger 
22 
patients. 
The adverse effects which occur subsequent to administration of 
morphine and other opioid drugs are well described. Actions on the 
central nervous system include "analgesia, drowsiness, changes in 
23 
mood, and mental clouding". As discussed by these authors, res-
piratory depression, nauseant and emetic effects, miosis, itching and 
hemodynamic changes are additional common effects of opioid agonists 
when used in therapeutic doses. 
Butorphanol tartrate is a opioid analgesic with agonist and 
antagonist activity. At present, there has been no investigation 
regarding the influence of age on the pharmacokinetic disposition of 
this drug, although such disposition is well characterized in young, 
24 
healthy human beings. Butorphanol is completely absorbed following 
4 
intramuscular and oral administration. However the oral bioavail-
ability is only about 17%, possibly secondary to extensive first pass 
metabolism. From available literature, it appears that the disposi-
tion of butorphanol is best described by a two compartmental model. 
Heel et al, cite results from animal investigations which demonstrate 
that butorphanol was widely distributed to excretory organs and 
highly perfused and fatty tissues. Butorphanol is 80% protein bound 
to human serum proteins.25 
In investigation of the disposition of butorphanol in subjects 
aged 22-28 years, it was observed that the drug was extensively 
metabolized to hydroxybutorphanol, with norbutorphanol a minor 
metabolite. Both of these are inactive when tested for analgesic 
activity and adverse effects. A mean of 71% of the administered dose 
was recovered in the urine, 7% as unchanged drug and 64% as metabo-
24 
lite, with the remainder of the dose eliminated in the feces. 
Unlike meperidine, butorphanol is metabolized to inactive 
25 
compounds, and does not inhibit gallbladder emptying, as has been 
2 6 
observed for morphine and other narcotics. In addition, butor-
phanol tartrate is purported to cause less respiratory depression 
than other narcotic analgesics, exhibiting a "ceiling effect" in that 
27 
increased doses do not produce increased respiratory depression. 
These advantages suggest that butorphanol may potentially be a 
suitable agent for relief of moderate to severe pain in the elderly 
population, without the problems associated with administration of 
other narcotic analgesics, as previously discussed. 
Butorphanol does have some affinity for sigma opioid receptors, 
which may result in dysphoria or hallucinations in some patients. 
5 
PURPOSE 
The purpose of this investigation was to examine the relative 
disposition of butorphanol tartrate in young and elderly male volun-
teers. In addition, data were collected to evaluate the effect age 
may have on the clinical manifestations of the common side effects of 
butorphanol. 
MATERIALS AND METHODS 
Subject Selection 
After an initial screening procedure, male subjects between the 
age of 20 to 40 and 60 to 99 years were recruited for paid partici-
pation in the study. For the screening, each subject received a 
twelve lead electrocardiogram and a complete physical examination, 
conducted by the study physician. A complete blood count with 
differential and platelet count, blood chemistry series and urinal-
ysis were also obtained and evaluated to determine study suitability. 
Subjects were excluded from participation if one of the follow-
ing existed; history of drug or alcohol abuse; history of opiate 
dependence; history of opiate hypersensitivity; allergy to butor-
phanol; outside of the age groups 20-40 and 60-99 years; outside the 
limits of 25% of their ideal body weight; decompensated congestive 
heart failure; chronic obstructive lung disease; consumption of any 
chronic medications which could not be discontinued prior to the 
study; or elevation of liver function tests greater than three times 
normal values. In addition, subjects were asked to refrain from 
ethanol and tobacco consumption for one week's time prior to their 
participation in the data collection phase of the study. All sub-




The Investigation was a non-randomized, open label, single dose 
pharmacokinetic study. Subjects were asked to fast for 12 hours 
prior to and for four hours after the administration of the study 
drug. During this period, water was permitted ad lib. 
All subjects reported to the Clinical Research Center at Univer-
sity Hospital, Salt Lake City, Utah, between 0600 and 0700 on the 
morning of the study, at which time two intravenous access sites were 
® 
placed. A 20 gauge lj" Angiocath (Deseret Medical, Inc., Salt Lake 
City, Utah) was placed in the non-dominant upper extremity to facili-
tate plasma sampling. In the contralateral arm, a 21 gauge 3/4" 
butterfly infusion set (Deseret Medical, Inc., Salt Lake City, Utah) 
was placed for drug administration. This was removed immediately 
after the study drug was administered intravenously. 
Following a baseline blood sample and measurement of blood 
pressure, pulse and respiratory rate, a single intravenous bolus dose 
+ 
of butorphanol tartrate 2.0 mg was injected over 30 to 60 seconds. 
The injection site was then flushed with 2 ml of saline. Subsequent 
blood samples were collected at 2, 5, 10, 15, 30, 45 minutes and 1, 
1.5, 2, 4, 6, 8, 12, and 24 hours from the time of drug administra-
tion, The first 1.5 milliliter (ml) of each sample were discarded to 
remove the heparin which was instilled after each sample collection 
* 
to maintain access site patency. Each sample was placed immediately 
® 
into a potassium EDTA Vacutainer tube (model 6452-Becton Dickinson 
+ 
lot #A5J04, expiration date January 1988, Bristol Laboratories, 
S^yracuse, New York 
10 units/cc of pork heparin manufactured by Elkins, Sinn, Inc., 
Cherry-Hill, New Jersey, was used for the heparin flush. 
7 
and Co., Rutherford, New Jersey) and refrigerated until centrifuga-
tion, which occurred within one hour. Samples were centrifuged for 
ten minutes at 3,000 revolutions per minute using a Sorvall Instru-
ments GLC - 4 general laboratory centrifuge. The plasma was then 
transferred by pipet and separated into two empty prelabeled plastic 
screw-capped containers for storage at -20°C. These plasma samples 
were frozen until all subjects had completed the data collection 
phase, at which time the plasma samples were sent for assay to 
Microanalytic Diagnostic Institute, Inc. of Laguna Hills, California. 
Vital signs, including blood pressure, pulse and respiratory 
rate were measured and recorded on a case report from (see Appendix 
B) every 15 minutes for 1/2 hour, every 1/2 hour for 1 1/2 hours, and 
every two hours for six hours. 
At these times a subjective assessment of the subject's degree 
of sedation was performed utilizing a four level scale developed by 
Bristol Laboratories (see Appendix C) . In addition, the subjects 
were asked in an open ended fashion how they felt at these times. 
Two meals, consisting of a general diet were offered to the 
subjects at four and eight hours after drug administration. Subjects 
were required to remain recumbent for two hours following drug 
administration and were discharged after the 12 hour plasma sample, 
with instructions to return at 24 hours for the final blood sampling. 
Butorphanol Assay 
Serum concentrations of butorphanol were determined at the 
Microanalytic Diagnostic Institute, Inc., of Laguna Hills, 
California, using a radioimmunoassay procedure. The assay is a 
second antibody radioimmunoassay for unchanged drug in plasma or 
8 
serum, with a lower limit of sensitivity of 0,030 ng/ml. The coeffi-
cients of variation were 13% and 12.7% at 0.1 and 1.0 ng/ml, 
respectively. Collected samples were shipped to this extramural site 
via Federal Express in insulated containers packed with dry ice. 
Pharmacokinetic Analysis 
Plasma drug concentrations obtained from the assay were used in 
TM 
graphical analysis with the MicroHonlin nonlinear regression 
analysis computer program (version 1.0).28 This involves the steps 
of curve stripping and non-linear regression analysis of the data. 
Formatted for MS-DOS computers, this program calculates the initial 
and refined estimates of the coefficients and exponents which are 
used to describe a specific compartmental pharmacokinetic model. 
Intercepts and slopes were checked by comparison with graphical 
analysis. These values were then used to calculate the pharmaco-
kinetic parameters of terminal elimination half-life, area under the 
curve to infinity and area under the moment curve to infinity. 
Values of clearance and apparent steady state volume of distribution 
were calculated using non-compartmental methods as described by 
29 
Gibaldl. This method can be applied to any compartmental model in 
which linear pharmacokinetics are assumed. (See Appendix D for the 
equations used in these calculations.) Pharmacokinetic parameters 
were calculated for each subject; then the arithmetic means for the 
young and elderly groups were calculated to facilitate comparison. 
Statistical Analysis 
Individual values obtained for clearance and apparent steady 
state volume of distribution were used in statistical comparison 
between the young and the elderly, by use of a Mann Whitney U test, 
9 
with the level of significance set a priori at p = 0.05. Assessment 
of differences in the mean changes in respiratory rate, were tested 
for statistical significance using the Mann Whitney U test, with a 
level of significance of p = 0.05. Changes in respiratory rate from 
baseline observation were plotted against serum butorphanol concen-
tration. A Spearman's rank correlation was performed on these data 
with the r and p values set a priori at 0.8 and 0.05, respectively. 
RESULTS 
Subject Selection 
Seventeen subjects were selected for participation in this 
study. Individual subject characteristics are reported in Table 1. 
Subjects 1 through 8 comprised the "young" group, with a mean age of 
27.75 (range 23-34) years, whereas subjects 9 through 17 were the 
"elderly" volunteers, with a mean age of 69.25 (range 65-79) years. 
Subjects 6 and 17 were excluded from pharmacokinetic analysis because 
of infiltration of butorphanol following injection. Subject 15 was 
excluded from analysis, as he was outside the acceptable limits for 
ideal body weight. 
Pertinent laboratory values obtained during the initial screen-
ing procedure are given in Table 2. 
Pharmacokinetic Analysis 
The pharmacokinetic parameters of clearance, apparent volume of 
distribution at steady state, terminal elimination half-life, area 
under the curve to infinity and area under the moment curve to 
infinity were derived for each subject. Individual values calculated 
for the above parameters, as well as for area under the moment curve 
are presented in Tables 3 and 4. Individual values of serum drug 
10 
concentration and time are presented in Appendix E. Computer 
generated nonlinear regression analysis plots of logarithmic serum 
drug concentrations versus time for each subject are given in 
Appendix F. Individual plasma concentration-time data were fitted to 
a biexponential equation in 5/7 of the young subjects and 4/7 of the 
elderly, A triexponential equation described the best fit in 2/7 
young and 3/7 elderly subjects. The refined coefficients and 
exponents generated by non-linear regression and used in calculation 
of the above values are reported in Table 5. The weighting of the 
non-linear regression plots for each subject are also reported in 
this table. (See Appendix D for equations used.) 
The elimination half-life was 3,72 ± 0,49 hours (mean ± standard 
deviation) in the young and 5.22 ± 2,91 hours in the elderly. The 
clearance of butorphanol following intravenous bolus administration 
was 1.71 ± 0.28 liters/hour/kilogram in the young and 1.53 + 0.43 
liters/hour/kilogram in the elderly. The apparent volume of distri-
bution at steady state was 8.33 ± 2.27 liters/kilogram in the young 
and 8.82 ± 2.52 liters/kilogram in the elderly. The value for area 
under the curve was calculated as 10.94 ± 2,35 mlcrogram-hour/liter 
for the young and 12.31 ± 4.98 mlcrogram-hour/liter for the elderly. 
Statistical analysis was performed for clearance and apparent 
volume of distribution at steady state using a Mann Whitney U test 
with the level of significance set a priori at p = 0.05. In each 
case, the critical value obtained from a table of probabilities 
associated with values as small as observed values of U in the Mann 
30 
Whitney 0 test was 0.50. (Sample size of n = 7 in each group, with 
a calculated U value of 24). Hence, no significant difference was 
11 
observed between young and elderly subjects for the parameters of 
clearance or apparent steady state volume of distribution. 
Vital Signs and Subjective Assessment 
The data within this section exclude subjects 6 and 17 since 
these individuals had extravasation of medication on infusion. This 
caused an alteration in the characteristics of pharmacodynamic 
response. 
Respiration - All subjects experienced a decline in respiratory 
rate following administration of butorphanol. The young group had a 
nadir of -7 ± 2 (mean ± standard deviation) breaths per minute (range 
-2 to -9) below baseline observation, ensuing 1.0 i 0.6 hours (range 
0.25 to 1,5 hours) after injection of the drug. The nadir in the 
elderly subjects was -5 ± 3 breaths per minute (range -2 to -12) from 
baseline observation, occurring at 0.9 ± 0.4 hours (range 0.25 to 1.5 
hours) after administration. 
In the young subjects, the duration of respiratory depression, 
as measured by changes in respiratory rate, ranged from an isolated 
recording at a single observation point to a period of two measure-
ments spanning one-half hour. In the elderly, the duration ranged 
from a single observation to a period of six measurements, spanning 
seven hours. Respiratory rates recorded for each subject and changes 
from baseline are listed in Tables 6 and 7. 
Statistical analysis of the greatest decrease in respiratory 
rate in each individual was performed using a Mann Whitney U test 
with the level of significance determined a priori at p = 0.05. The 
results of this test failed to show a statistically significant 
difference between the young and elderly subjects. 
12 
Pulse - Subjects exhibited a highly variable change in pulse 
after drug administration. The greatest absolute deviation from 
baseline for the young subjects was 13 ± 5 beats per minute (mean ± 
SD), ranging from a minimum change of 4 beats per minute to 20 beats 
per minute. 
For the elderly individuals, the greatest absolute deviation 
from baseline was 13 ± 6 beats per minute. This ranged from a 
minimum decline of four beats per minute to a gain of 24 beats per 
minute. Individual measurements of pulse can be found in Tables 8 
and 9. 
Blood Pressure - Changes in blood pressure following injection 
of butorphanol were also highly variable with no discernible trend 
noted. In the young subjects, the greatest absolute change in 
systolic pressure was 17 ± 8 mm Hg (range 8 mm Hg to 30 mm Hg). The 
greatest absolute change in diastolic pressure was 17 ± 5 mm Hg 
(range: 10 mm Hg to 20 mm Hg). 
In the elderly subjects, the greatest absolute change in 
systolic pressure was 16.0 + 8.0 mm Hg (range: 10 mm Hg to 30 mm Hg. 
The greatest absolute change in diastolic pressure was 13 ± 4 mm Hg 
(range: 8 mm Hg to 18 mm Hg). Individual blood pressure readings are 
included in Tables 10 and 11. 
Sedation - All subjects experienced some degree of sedation 
following administration of butorphanol. The peak sedation experi-
enced by young subjects was 2 ± 1 (mean ± SD) (range 1 to 3) on a 
scale of 0 to 3. (See Appendix C for an explanation of this scale.) 
The elderly were judged to have a degree of sedation of 2 ± 1 (range 
1 to 2), using the same criteria. The time of onset of greatest 
13 
sedation observed was 1.1 ± 0.8 hours in the young and 0.5 ± 0.3 
hours in the elderly. 
In the young subjects, the duration of the greatest degree of 
sedation ranged from one observation to five observations, spanning a 
period from 0.25 to 2 hours. The duration of the greatest degree of 
sedation in the elderly ranged from three observations spanning a 
period from 0.25 to 1 hour to five observations, spanning a period 
from 0.25 to 2 hours. 
Recordings of the sedation scale for each subject are listed in 
Tables 12 and 13. the degree, time of onset and duration of greatest 
sedation are noted in Table 14. 
Adverse Effects - Several subjects experienced adverse effects 
incident to the administration of butorphanol. Most common was 
dry mouth In three elderly and two young subjects (5/14 - 36%). In 
addition diaphoresis occurred in three young and one elderly subjects 
(4/14-29%). This was followed by tingling and numbness, headache, 
dizziness, and itching, each of which were experienced by 3/14 
subjects (21%). These side effects were distributed between the 
young and elderly subjects, with none noted exclusively for one age 
group. One subject (13) from the elderly group experienced nausea 
and vomiting. 
All adverse drug experiences abated with time alone, except two 
cases of headache which were treated with acetaminophen (subject 13 -
650 mg; subject 7 - 975 mg) , with both cases resulting in resolution 
of symptoms. The third subject who experienced a headache first 
reported the manifestation 24 hours after drug administration and was 
not treated with any medication. 
14 
Several other unique side effects were recorded, most notably 
those experienced by subject 7, who initially reported "feeling 
relaxed" at ten minutes, then noted visual changes at 15 minutes. 
This progressed to a period of profound sedation during which time 
the subject was observed to be grimacing, muttering, singing and 
moving all extremities. This resolved with verbal reassurance from 
the investigator. After awakening, the subject could not recall any 
of these events. 
Subject 2 attempted to perform arithmetic manipulations 2 hours 
after drug administration and found that he "could not concentrate". 
Subject 14 stated that he felt as if he had to "force himself to 
breath". Euphoria was reported by two of the young subjects (7,8), 
however, the initial euphoria in subject 7 appeared to be subsequent-
ly manifested as dysphoria (see above). No elderly subject reported 
experience euphoria or dysphoria. 
Three individuals, one young and two elderly experienced no 
adverse reactions following injection of butorphanol. A listing of 
side effects noted for each individual can be found in Table 15. 
Common side effects, experienced by two or more subjects are listed 
in Table 16. 
In subjects 6 and 17, butorphanol infiltrated following adminis-
tration. Because of the subsequent changes in absorption charac-
teristics, it is necessary to comment on the changes in vital signs 
and subjective effects separately from the above. 
Subject 6 experienced a peak decrease of four breaths per minute 
below baseline in his respiratory rate at 30 minutes following drug 
administration. In addition, the peak absolute change in pulse was 
15 
18 beats per minute, two hours after injection; the peak absolute 
change in systolic and diastolic blood pressure were 24 and 20 mm Hg, 
respectively. Side effects of the drug were limited to flushing and 
sweating. 
Subject 17 experienced a peak decrease of two breaths per minute 
in his respiratory rate, at 15 minutes following injection. In 
addition, the peak absolute change in pulse was 22 beats per minute, 
15 minutes after injection; the peak absolute change in systolic and 
diastolic pressure were 52 and 24 mm Hg, respectively. This indi-
vidual experienced nausea and vomiting which was treated with 1.25 mg 
droperidol given intravenously, with resolution of symptoms. 
DISCUSSION 
Pharmacokinetic Analysis 
Several studies have investigated the influence of age on the 
pharmacokinetic parameters associated with narcotic analgesics. In a 
clinical Investigation of morphine sulfate, the percent of the drug 
bound to plasma albumin was found to be a function of the concentra-
15 
tion of this protein. Also, an increase in the peak serum concen-
16 17 tration, prolongation of the apparent elimination half-life, and 
an increase in the mean apparent volume of distribution^ have been 
observed in elderly patients when compared to young adults. 
Investigation with meperidine has revealed similar age related 
changes. In their study of nine elderly and six young patients, 
Holmberg and colleagues reported a significant increase in the 
18 
elimination half-life in the elders. Other pharmacokinetic para-
meters reflected this difference between the two groups, with a 
decrease in body clearance and a greater area under the curve noted 
16 
for the elderly group. No significant difference in the apparent 
volume of distribution between the elderly and young was observed in 
this study. 
19 
In an assessment of fentanyl pharmacokinetics, Bently et al, 
observed a significant prolongation of the elimination half-life and 
a decreased clearance. No significant difference in the apparent 
volume of distribution between the elderly and young was observed. 
Alfentanil, which is chemically related to fentanyl, has also been 
noted to exhibit an increased elimination half-life and decreased 
clearance when administered to elderly patients, yet no change in the 
20 
volume of distribution was observed. 
One investigation of propoxyphene administered orally as a 
single dose was performed. Unlike the previously discussed studies, 
this investigation revealed no differences between elderly and young 
patients in the peak concentration, time to reach peak concentration, 
or area under the plasma concentration versus time curve to infinity 
when the compound was administered to young and elderly 
21 
individuals. 
In the present investigation of butorphanol, the pharmacokinetic 
parameters of clearance, apparent volume of distribution at steady 
state, elimination half-life, area under the curve to infinity and 
area under the moment curve to infinity revealed no significant 
difference between elderly and young subjects. The area under the 
curve to infinity, calculated to be 10.94 ± 2.35 meg-hr/liter in the 
young and 12.31 ± 4.98 mcg-hr/liter in the elderly. The value 
calculated for the young was consistent with previously reported 
values of Gaver et al, who studied the disposition of parenteral 
24 
butorphanol in six healthy male subjects, age 22 to 28 years. 
17 
The estimated terminal elimination half-life for the young of 
3.72 ± 0.49 hours also agrees with the work of Gaver et al, who 
24 
reported a range of 3-4 hours. In the current investigation, the 
elderly subjects did exhibit a slightly prolonged elimination half-
life. Statistical analysis of this value was not performed since the 
apparent elimination half-life is influenced by the independent 
parameters of clearance and apparent steady state volume of distribu-
tion. Statistical analysis of these independent values revealed no 
significant difference between the young and the old. In turn, small 
changes in these values could account for observed changes in the 
apparent elimination half-life. 
Several factors may explain the apparent lack of difference in 
the disposition of butorphanol between elderly and young subjects. 
The sample size analyzed is small and may not reflect actual popula-
tion parameters. This study found no difference between the two 
treatment groups and could have detected a 37% difference with a 
power of 0.8, Perhaps if a greater number of subjects had been 
studied, a difference would have been manifested. 
Secondly, the mean age of the elderly subjects was 69.25 years, 
which may not have been great enough to find a difference. Rowe and 
Besdine distinguish between the "young - old" and the "old - old", 
with those individuals between 65 and 75 years comprising the 
31 
former. In the "young - old", according to Rose and Bedsine, the 
physiologic changes which occur generally do not have a major 
clinical impact. It is in the "old - old" (greater than 75 years) 
that major clinical manifestations may be associated with the aging 
physiologic system. 
18 
Beyond this distinction, the confounding variable of chronologic 
versus biologic age is worth examining. Mayersohn suggests that this 
difficulty in distinguishing between biologic and chronologic age is 
a major concern in the interpretation of studies involving geriatric 
32 
patients. The impediment in interpretation arises from the obser-
vation that individuals have markedly different rates of biological 
aging. As a result of the dramatic variation in the aging process, 
Mayersohn suggests it is often difficult to make generalizations 
regarding the pharmacokinetic disposition of drugs. As discussed by 
lowe, there has not been an adequate marker developed to measure 
functional (or biological) age, making the Interpretation of biologi-
33 
cal age difficult. 
The inadequacy of using chronological age as a predictor of 
pharmacokinetic disposition is demonstrable by an examination of the 
present data. Of note is the characterization of the pharmacokinetic 
disposition of butorphanol in subject 16, aged 79 years. The clear-
ance was calculated to be 1.53 liters/hour/kilogram, which is very 
similar to the mean value of 1.53 ± 0.43 liters/hour/kilogram 
obtained for the elderly. The apparent steady state volume of 
distribution was 8.36 liters/kilogram which was even more consistent 
with the mean value of 8.33 ± 2.27 liters/kilogram calculated for the 
young, than the mean value of 8.82 ± 2.52 liters/kilogram calculated 
for the elderly. 
It is interesting to note that there was consistently greater 
variance in the pharmacokinetic parameters for the elderly subjects 
than the young, as reflected in the calculated standard deviations 
and ranges. This is demonstrable by examining the values obtained 
19 
for clearance In the elderly. These ranged from 0.88 liters/hour/ 
kilogram (subject 11) to 2.27 liters/hour/kilogram (subject 12). In 
addition the values for the apparent steady state volume of distribu-
tion in the elderly ranged from 5.89 liters/kilogram (subject 13) to 
13.4 liters/kilogram (subject 11). 
Variability in drug disposition for elderly subjects has been 
alluded to often, yet a limited number of studies provide support for 
this observation. Melander et al, stated that their elderly subjects 
showed a "pronounced" and "considerable" interindivldual variation in 
the pharmacokinetic parameters studied following oral administration 
20 
of propoxyphene, Berkowitz et al, suggested that early serum 
levels of morphine were "more variable" in their elderly patients 
than the young counterparts.^ The current observation suggests that 
there is less homogeneity of butorphanol disposition in elderly 
subjects. Increased variance in subjects decreases the ability to 
detect a significant difference. 
Finally, it is necessary to consider that the lack of pharmaco-
kinetic difference observed may indeed reflect no change between the 
young and old for this drug. This apparent lack of difference 
warrants further exploration. As discussed previously, butorphanol 
is extensively metabolized with negligible renal clearance. There-
fore, the total body clearance of butorphanol approximates its 
hepatic clearance. From bioavailability data, it may be deduced that 
butorphanol has a high hepatic extraction ratio. Drugs with high 
hepatic extraction ratios are termed "flow-dependent" or "perfusion 
rate-limited" since hepatic blood flow has the greatest influence in 
determining the rate of clearance of the drug. Therefore, changes in 
20 
hepatic blood flow should alter the clearance of a highly hepatic 
extracted drug. Provided total body clearance approximates hepatic 
clearance, then changes in hepatic blood flow should also affect 
total body clearance. 
In previous investigations, it was observed that the clearance 
of morphine, meperidine and fentanyl were decreased in the 
18 19 35 
elderly, ' ' which would be consistent with the decline in 
8 
hepatic blood flow traditionally associated with physiologic aging. 
That a decrease in clearance in the elderly of the present investiga-
tion was not seen is a puzzling observation. This is not consistent 
with the concept of "flow-dependent" hepatic clearance as discussed 
above. Perhaps several other factors, not directly assessed in this 
investigation, may have negated the effects of reduced hepatic blood 
flow if present in the elderly population. 
The subjects selected for this study were healthy ambulatory 
males, which contrasts to the previously cited investigations, 
involving surgical patients. In addition, in these investigations 
the patients were often concomitantly administered other drugs which 
may have influenced the disposition of the narcotic analgesic, studied. 
Neither of these concerns were addressed in the previous studies. 
As discussed above, the variance associated with biologic age 
may be important, with the current sample representing a "younger" 
group. Although assessment of one organ system does not predict 
overall biologic functioning, it is interesting to note that all 
elderly subjects had good age adjusted renal function, as reflected 
by calculated creatinine clearances, ranging from 49.8 ml/minute to 
70 ml/minute (see Table 2). Therefore, the elderly sample in this 
21 
investigation may represent a portion of the "healthy" elderly who 
demonstrate adequate organ perfusion in later life. 
In addition, the effect of red cell and plasma protein binding 
on metabolism must be considered. However, as discussed by Rowland 
and Tozer, these effects should not influence either the extraction 
a i 
ratio or clearance of high hepatic extraction ratio drugs. 
In their investigation of lidocaine kinetics in aged subjects, 
Nation et al studied the rate of clearance of the drug between 
36 
elderly and young subjects. Lidocaine, like butorphanol, is 
characterized by flow - dependent hepatic elimination with minimal 
urinary elimination of unchanged drug. As such, one would also 
expect to see a decline in total clearance with aging, yet this was 
not observed. No significant difference in the rate of clearance 
between elderly and young subjects was observed. As with the present 
investigation, this suggests that some other mechanism may be compen-
sating for the expected decline in hepatic blood flow from chrono-
logical age alone. The authors suggest that an opposing shift in 
extraction greater than expected or a compensatory metabolic clear-
ance by another organ which is not an important route of elimination 
in young subjects may be potential mechanisms for this adjustment. 
In addition, it is Important to realize that in the above 
investigations with morphine, meperidine and fentanyl, no attempt was 
made to assess the rate of hepatic blood flow in order to determine 
the underlying mechanism for decreased drug clearance. Recent 
evidence suggests that there may indeed be no decline in cardiac 
9 
output as a function of aging. This in turn leads to the specula-
tion that hepatic blood flow may not actually decline as a function 
22 
of age. Perhaps it would be prudent to reassess the results of 
earlier investigations in light of this recent clinical evidence 
regarding cardiac output. In addition, it may be worthwhile to 
assess hepatic blood flow when studying the pharmacokinetic dispo-
sition of narcotic analgesics in elderly individuals. 
Quantification of urinary and fecal excretion of butorphanol and 
it metabolites was not attempted in this investigation. Because of 
this, it is not possible to definitively assess whether the similar-
ity in the rate of clearance between the elderly and the young 
reflects variation in the elderly and selection of a younger biologic 
sample, or if in fact compensatory adjustments in elimination occur 
secondary to a probable decline in hepatic blood flow. Further 
characterization of the pattern of urinary and fecal metabolites of 
butorphanol in the elderly may be a potential area for investigation. 
Vital Signs and Subjective Assessment 
Respiratory depression is well documented following opioid 
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administration. Martin cites evidence which suggests this effect 
is secondary to an interference with the respiratory modulator 
process of the central nervous system, A decrease in the respon-
sivity of the respiratory center to CO^ and selective depression of 
neuronal modulation of the respiratory center are given as probable 
mechanisms.37 38 27 Research by Popio et al, and Nagashima et al, suggest that 
similar respiratory depression occurs with butorphanol. However, a 
major difference between morphine and butorphanol, as suggested by 
the results of Nagashima et al, is a potential limit to the respira-
tory depressant effects of butorphanol when larger doses are 
23 
administered. This observation, often termed a "ceiling effect", 
does not occur with morphine and other closely related opioids. Both 
of these investigations reported on the mean + SEM respiratory rate 
recorded at predetermined intervals following butorphanol adminis-
tration. (Doses were 30 mcg/kg and 60 mcg/kg for Nagashiraa and 25 
mcg/kg for Popio.) In both investigations, statistical analysis 
using a paired Student's test revealed no significant change in 
respiratory rate between pre- and post-drug administration 
assessments. 
In the present investigation, respiratory rates were recorded at 
predetermined intervals and changes from baseline observation for 
each subject were noted. Statistical comparison between the young 
and elderly groups of the greatest decline in respiratory rate from 
baseline was accomplished by using a Mann Whitney U test. This was 
performed in an attempt to determine whether age would influence the 
respiratory rate after butorphanol administration. As noted previ-
ously, no significant difference was found between the two groups. 
However, a trend toward a greater decrease in the rate in the young 
people was evident. 
In addition to rate, narcotic analgesics also may affect other 
characteristics of respiration. Several parameters, such as the 
rhythmicity and patterns of respirations, minute volume and respon-
23 
sivity to C02 can be affected, but were not assessed in this 
investigation. Briefly noted however were effects in subject 12 who 
experienced a 10 second period of apnea at 60 minutes, and subject 14 
who subjectively reported that he felt as if he had to force himself 
to breathe. None of these effects was noted in the young. However 
they were not specifically intended to be addressed a priori. 
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From this limited observation, the respiratory effects of 
butorphanol appeared to be well tolerated without incident by elderly 
individuals. This is demonstrable by noting that the young subjects, 
in all but two cases, exhibited decreases in respiratory rates at 
least as great as their elderly counterparts. Only one older person 
(subject 12) had a notable response, with a decrease of twelve 
breaths per minute. It should be noted that individuals were exclud-
ed from participation for any history of underlying lung disease. 
The effects of butorphanol in this subset of the elderly population 
have not been investigated and could potentially result in more 
serious impairment of respiratory function. 
Less consistent changes were noted for pulse and blood pressure. 
Opioid drugs generally have had varied hemodynamic effects with 
factors such as the particular drug or species studied influencing 
37 
the results. In human investigation of butorphanol, several 
studies have attempted to elucidate these cardiovascular effects. 
39 
Dobkin et al, assessed the safety and efficacy of butorphanol In 
150 patients treated intramuscularly for post-operative pain. Little 
data is reported regarding cardiovascular effects, yet the authors 
state that none of the patients experienced marked changes in blood 
40 
pressure. In part 2 of this report, the safety and efficacy of 
butorphanol in balanced anesthesia for 53 patients was evaluated. 
Again, no actual data is given for specific hemodynamic changes, yet 
the authors reported an increase in arterial blood pressure through-
out the operation. This was attributed however, to changes in the 
recording of pressure, done from an arterial cannula during the 
procedure Instead of auscultation with a manometer, as before. 
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More detailed Information regarding the hemodynamic effects of 
38 
butorphanol is available by examining the work of Popio et al. In 
their investigation of twenty patients undergoing cardiac catheteri-
zation, no change in heart rate was observed following 0.025 mg/kg of 
butorphanol. Decreases in peripheral resistance and increases in 
cardiac index and pulmonary artery pressure were noted. In the 
present experience, no clinically significant changes in heart rate 
(pulse) or blood pressure were observed. 
This apparent lack of difference in vital sign changes and 
tolerance of the effects of the drug between the young and the 
elderly was unexpected, as elderly patients are often described as 
being "more sensitive" to the adverse effects of drugs. The present 
observation may be partially explained by examining the relationship 
between plasma drug concentrations and clinical manifestations of 
narcotic analgesics. Inturrisi and Verebely studied the disposition 
41 
of methadone in man after a single oral dose. The time action of 
pupillary constriction caused by methadone, a common effect following 
administration of narcotic analgesics, was related to the plasma 
concentration of the drug. It was observed that the onset, peak and 
duration of pupillary constriction corresponded with the plasma 
concentrations curve for methadone. The authors also cite an earlier 
study in which the Intensity and duration of the miotic response to 
many narcotic analgesics correlated with other side effects such as 
drowsiness and euphoria.42 
However, an examination of dose response relationships for 
37 
butorphanol, as reviewed by Martin, provides further insight. As 
previously described, butorphanol lacks such a relationship for its 
26 
effect on respiration. In addition, butorphanol's effect on miosis 
is dissimilar to that previously described for methadone, Butor-
phanol produces a dose-related miosis in intramuscular doses of 2 rag 
and 4 mg, yet 8 mg is associated with a lesser degree of miosis than 
37 
4 mg, Martin also describes investigations for which there is 
evidence that a dose-response relationship exists for the analgesic, 
sedative and dysphoric effects, but not the euphoric effects follow-
37 
ing administration of butorphanol. 
Although a single dose was administered in the present investi-
gation, it is possible to assume some relationship between dose and 
plasma concentration, such that much of the previous discussion of 
dose-response relationships would also be consistent with plasma 
concentration and response. The apparent lack of the relationship 
between respiratory depression and plasma concentration for 
butorphanol is revealed by examining the results of the present 
investigation. A scattergram of the plasma concentration of butor-
phanol versus decreases (from baseline) in respiratory rate, revealed 
no association. A Spearman's rank correlation of this plot did not 
achieve statistical significance. (See Figure 1.) 
In addition, the apparent lack of change in vital signs may be 
due to many variables, several of which are worth exploring. First, 
baseline vital signs were recorded after insertion of the angiocath 
and butterfly infusion set for some subjects. for individuals in 
whom multiple attempts were necessary for needle insertion, or for 
those with an apprehension associated with "needle sticks", there may 
have been a transient alteration from actual resting vital signs. In 
most cases, however, a 10 to 15 minute interval between needle 
27 
insertion and measurement of vital signs was present, minimizing this 
6 f f G C t » 
Similar to this, vital signs were not consistently measured for 
all subjects in relation to blood draws during data collection. The 
assessments were made either before, during or after collection of 
the blood sample, depending on the timing of the blood draw and the 
investigator responsible for vital sign measurement. In addition, 
although precautions were taken to ensure consistency, more than one 
investigator may have assessed the vital signs at different times. 
Another source of variation can be related to the effect of 
position. Changes in blood pressure related to supine, sitting or 
standing positions are well known. Of special consideration is the 
27 
change noted by Nagashima et al. When their patients were placed 
in a 30 degree head-up position, an increase in heart rate and blood 
pressure was noted for both treated and non-treated subjects. In the 
present investigation, all subjects remained supine, however, the 
head position was not controlled. Whether the above factors 
influenced the assessment of vital signs must remain speculation. 
Assessment of sedation following narcotic administration can be 
a difficult non-reproducible task. Both the young and the elderly 
appeared to be equally sedated, however there was some suggestion 
that more variability in response existed for the young subjects, in 
that the degree of greatest sedation ranged from 1 to 3, whereas no 
score of 3 was noted for the elderly subjects. The observations also 
suggested that a shorter period of time elapsed before the onset of 
peak sedation for the elderly. (See Tables 12-14, Appendix C.) 
28 
The use of the scale In the current Investigation was new to the 
investigators which may have influenced the consistency of assess-
ment. This issue may have resolved with time as the investigators 
became more familiar with the use of the scale. In addition, exter-
nal stimuli were not controlled, such that there was considerable 
variation between data collection periods. During the early period 
of rapidly occurring sample times (i.e. 2, 5, 10, and 15 minutes) 
there was excessive activity and movement of the investigators and 
nurses, which may not reflect the environment which occurs when 
individuals are given the drug for therapeutic purposes. 
Several side effects were manifested in the present experience. 
Sedation, as discussed above, was experienced to some extent by all 
subjects. The most common adverse effects associated with butor-
phanol are sedation (37%), nausea (75%), clamminess/sweating (5%), 
43 
and headache (2%). In the present investigation, all of these 
effects were experienced by different subjects, as discussed 
previously. Because of the small sample size used, it is not 
instructive to compare the incidence of adverse effects between this 
investigation and that reported in the literature. Of note, however, 
is that the drug was tolerated equally well between the young and 
elderly subjects. 
One factor which may have influenced the subjective experience 
following drug administration is related to communication between 
subjects. It is interesting to note that experiences appeared to be 
influenced by individuals who underwent the data collection phase of 
the study together. Two subjects were commonly placed together in 
the same room, with the clinical manifestations of one subject 
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observed by the other. As an example, the two young subjects who 
experienced euphoria were studied together. In addition, two of the 
three subjects who experienced a headache (subjects 12 and 13} were 
in the same room. It is possible that these settings may have 
influenced the subjective experience. In addition, several young 
subjects reported their experiences to other young individuals who 
were to be studied at a future time. This may have increased the 
expectations of the young group more that the elderly, as the latter 
did not have this benefit of communication due to the lack of 
fraternization. 
Several of the differences observed between butorphanol and 
other opioid analgesics may be explained by varying opioid receptor 
type affinities. Morphine, meperidine and methadone are primarily mu 
receptor agonists with some agonist activity on kappa and sigma 
receptors as well. Butorphanol is primarily a kappa agonist and mu 
antagonist with relatively more agonist potential than the other 
narcotic analgesics mentioned above. 
The mu receptor is primarily associated with supraspinal 
analgesia, respiratory depression, sedation and euphoria. The kappa 
receptor is primarily associated with spinal analgesia, sedation and 
miosis. The sigma receptor is primarily associated with dysphoria, 
hallucinations and psychomotor stimulation. The relative effects of 
these drugs on the delta receptor,which appears to be associated with 
changes in affective behavior, are unclear. 
Finally, it is intersting to note that all of the young sub-
jects, with the exception of subject 8, were pharmacists. With a 
background knowledge of narcotic analagesics, these individuals may 
30 
have had prior expectations regarding their subjective experience 
following drug administration, 
CONCLUSION 
In this investigation, seventeen male subjects were given a 
single intravenous dose of butorphanol tartrate. The drug appeared 
to be well tolerated by all subjects, with adverse effects equally 
distributed between the young and old- As discussed above, no 
significant difference was noted for the parameters of clearance and 
volume of distribution at steady state which were subjected to 
statistical analysis. However, a trend toward a longer elimination 
half-life, with a small decrease in the rate of clearance was noted 
for the elderly subjects. 
Several reasons for the apparent lack of difference have been 
discussed, which suggest further areas for research, A greater number 
of subjects, with an older mean age for the elderly group would be 
one avenue to explore. In addition, a multiple-dose investigation, 
as opposed to the single dose assessment performed here, may reflect 
a more accurate characterization of the pharmacokinetic disposition 
in therapeutic regimens as well as provide insight to possible 
accumulation and linearity. 
To this point, research with morphine, meperidine, fentanyl and 
alfentanil have provided an initial indication of age related changes 
in the pharmacokinetic and pharmacodynamic responses to narcotic 
analgesics. The present study suggests that butorphanol may poten-
tially be a suitable agent for pain relief in the elderly. Based on 
the current investigation, it appears that no overall adjustment in 
dose is required when administering butorphanol to elderly patients. 
31 
Again, however, it is necessary to consider each patient individ-
ually. An assessment of physiologic integrity based on examination 
of renal and hepatic function, integrating other pertinent variable 
such as concomitantly administered drugs and the overall clinical 
status of the patient will assist the clinician in determining the 
most appropriate pharmacologic therapy. 
Because the purpose of this study was to characterize the 
pharmacokinetic disposition of butorphanol, there was no attempt to 
assess the degree of pain relief obtained subsequent to butorphanol 
administration. Therefore, comparison of the efficacy, both in degree 
and duration of pain relief, following butorphanol administration in 
relation to other narcotic analgesics is another potential area for 
investigation. 
It is through continued investigation with these agents that 
effective and safe analgesia may be obtained for the geriatric 
population. 
TABLES 
TABLE 1. SUBJECT CHARACTERISTICS 
SUBJECT AGE+ HEIGHT* IDEAL BODY WEIGHT ACTUAL BODY WEIGHT 
01 23 178 73.5 73.5 
02 24 162 74.2 69.3 
03 25 169 65.0 63.0 
04 29 188 82.2 69.8 
05 26 183 77.6 77.3 
06 29 193 86.8 84.1 
07 34 185 79.9 91.5 
08 32 175 70.7 83.3 
09 68 180 74.7 95.5 
10 67 178 73.0 74.5 
11 68 173 68.4 66.3 
12 66 173 68.4 71.5 
13 65 178 73.0 85.5 
14 65 188 82.2 79.3 
16 79 178 73.0 79.8 
17 76 178 73.0 87.3 
+ 
age in years 
it 
"height in centimeters **weight in kilograms, ideal body weight calculated by: 
50+2.3 (inches over 5 feet) = weight in kilograms 
(Subject 15 not included in study, data not available.) 













































































































































































KEY: S cr = serum creatinine (0.8-1.4 mg/dl) _ 
Cr cl = estimated creatinine clearance calculated as:(140 - age)(ideal body weight)/(72)(S cr) (mL/min) 
Tot pr - total protein (6.3-7.9 g/dl) 
Ablumin = (3.9-5.0 gm/dl) 
Alk Phos = alkaline phosphatase (44-147 IU/L) 
LD = lactate dehydrogenase (133-333 IU/L) 
AST = aspartate aminotrausferase (SGOT)(9-55 IU/L) 
ALT = alanine aminotransferase (SGPT)(6-59 IU/L) 
GT = glutamyl transferase (11-51 IU/L) 
+normal values for ARUP Clinical Laboratories, Salt Lake City, Utah 
Co 
-IN 
TABLE 3. PHARMACOKINETIC PARAMETERS CALCULATED FOR YOUNG SUBJECTS 
Subject tj alpha K el tj terminal AUC to infinity AUMC to infinity CI tot Vd ss 
1 7.2 0.19 3.65 13.0 55.43 1.42 6.07 
2 5.94 0.23 3.01 11.87 47.04 1.65 6.55 
3 8.86 0.20 3.46 14.16 86.48 1.52 7.16 
4 3.38 0.16 4.33 11.44 64.28 1.70 9.57 
5 3.96 0.15 4.62 8.17 48.26 2.15 12.72 
7 9.24 0.18 3.85 9.98 51.11 1.49 7.63 
8 6.93 0.22 3.15 7.99 33.77 2.04 8.63 
mean+SD 6.5042.24 0.19+0.03 3.72±0.49 10.94+2.35 52.33±11.12 1.71+0.28 8.33±2.. 
KEY: t, alpha = distribution half-life (minutes) 5 -1 K el = elimination rate constant (hours ) 
tj terminal = terminal elimination half-life (hours) 
AUC to infinity = area under the curve to infinity (mcg-hr/L) 
2 
AUMC to infinity = area under the moment curve to infinity (mcg-hr /L) 
Vd ss = apparent volume of distribution at steady state (L/kg) 
€1 tot = steady state clearance (L/hr/kg) 
Ul 
TABLE 4. PHARMACOKINETIC PARAMETERS CALCULATED FOR ELDERLY SUBJECTS 
Subject tj alpha K el tj terminal AUC to infinity AUMC to infinity CI tot Vd ss 
9 11.48 0.15 4.62 10.81 63.48 1.32 7.74 
10 2.08 0.13 5.33 11.15 71.22 1.59 10.46 
11 2.08 0.06 11.55 23.28 353.99 0.88 13.4 
12 9.3 0.21 3.3 8.39 33.86 2.27 9.15 
13 2.05 0.17 4.08 11.87 52.13 1.34 5.89 
14 8.32 0.23 3.01 9.55 35.81 1.8 6.73 
16 12.56 0.15 4.62 11.12 60.61 1.53 8.36 
mean+SD 6.84±4.67 0.16±0.06 5.22±2.91 12.31±4.98 95.87+114.6 1.53±0.43 8.82±2.52 
KEY: t, alpha = distribution half-life (minutes) S 
K el = elimination rate constant (hours ) 
t| terminal = terminal elimination half-life (hours) 
AUC to infinity = area under the curve to infinity (mcg-hr/L) 
2 
AUMC to infinity = area under the moment curve to infinity (mcg-hr /L) 
Vd ss = apparent volume of distribution at steady state (L/kg) 
CI tot ® steady state clearance (L/hr/kg) u> cri 
TABLE 5. REFINED COEFFICIENTS AND EXPONENTS GENERATED BY NON-LINEAR REGRESSION AND USED IN 


















































9 1/y 4.85 3.62 1.42 0.15 
10 1/y 6.59 20.00 1.19 0.13 3.54 2.12 
11 1/y 8.27 20.00 1.27 0.06 2.44 1.43 
12 1/y 6.00 4.48 1.48 0.21 
13 1/y 22.00 20.25 1.47 0.17 3.79 1.77 
14 1/y 6.86 5.00 1.88 0.23 
16 1/y 7.00 3.31 1.35 0.15 
Key: 
A = Coeffieent of the first exponential term 
a = Exponent multiplying t In the first exponential term 
B = Coefficient of the terminal exponential term 
6 = Exponent multiplying t in the terminal exponential term 
C = Coefficient of the second exponential term in a three compartmental model 
II = Exponent multiplying t in the second exponential term of a three compartmental model Lj 
TABLE 6. RECORDED RESPIRATORY RATES (AND CHANGES FROM 
BASELINE) FOR YOUNG SUBJECTS* 
TIME 
I 2 3 
Baseline 18 18 14 
5 min 20(4-2) 14(-4) 16(+2) 
30 min 20(+2) 10(-8) 14(0) 
1 hr 12(—6) 9(-9) 12(-2) 
1.5 hr 15(—3) 9C-9) 18(+4) 
2 hr 15(-3) 13(—5) 14(0) 
4 hr 14(-4) 14(-4) 16(+2) 
6 hr 16(—2) 16(—2) 20(+6) 
8 hr 14(-4) 14(-4) 20(+6) 
Greatest 
Decline (-6) (-9) (-2) 
SUBJECTS 
4 5 6 7 8 
20 18 16 20 18 
12(-8) 16(-2) 14(-2) 12(—8) -
16(4) 16(—2) 12 (-4) 12(—8) 12 (-6) 
18(-2) 16(-2) 12(-4) 16<-4) 12(-6) 
18(-2) 16(-2) 12 (-4) 16(-4) 10(-8) 
18(-2) 12(-6) 14(-2) 16(-4) 14(-4) 
18 (-2) 16(-2) 14 (-2) 16(-4) 14(-4) 
20(0) 16C-2) 14(-2) 20(0) 14(-4) 
18(-2) 16(-2) 14<-2) 16(-4) 16(—2) 
(-8) (-6) (-4) (-8) (-8) 
Mean greatest decline: 7 + 2 (values for subject 6 excluded due to 
infiltration) + 
Values are in breaths per minute 
39 
TABLE 7. RECORDED RESPIRATORY RATES (AND CHANGE "FROM 
BASELINE) FOR ELDERLY SUB.JECTS+ 
TIME 
9 10 II 
Baseline 16 12 20 
15 min 14(-2) 16(+4) 18(-2) 
30 min 12(—4) 10(-2) 22(+2) 
1 hr 12(-4) 12(0) 16(-4) 
1.5 hr 12(-4) 16(+4) 16(—4) 
2 hr 12(-4) 16(4-4) 16(-4) 
4 hr 14(-4) 12(0) 16(-4) 
6 hr 18(+2) 16(+4) 16(—4) 
8 hr 14(-2) 16(+4) 16(-4) 
Greatest 
Decline (-4) (-2) (-4) 
SUBJECTS 
i i 13 i i 11 17 
22 18 16 20 16 
_ 18(0) 18(+2) 16(-4) 14(-2) 
14(-8) 16(-2) 14(-2) 18(-2) 14(-2) 
11(-11) 14(—4) 14(-2) 18(-2) 14(-2) 
10(-12) 12C-6) 14(-2) 18(-2) 18(+2) 
- 14(—4) 14(-2) 18(—2) 16(0) 
16(-6) 16C-2) 14(-2) 18(-2) 14(-2) 
16(-6) 16(-2) 16(0) 18(-2) 14(—2) 
16(—6) 16(-2) 16(0) 18(-2) 16(-2) 
(-12) (-6) (-2) (-4) (-2) 
Mean greatest decline: 5 ± 3 (Values for subject 17 excluded due to 
infiltration) + 
Values in breaths per minute 
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TABLE 8. RECORDED PULSE (AND CHANGES FROM BASELINE) 
FOR YOUNG SUBJECTS4" 
TIME 
1 2 
Baseline 60 60 
0.25 hr 58(—2) 50(—10) 
0.50 hr 64(+4) 50(—10) 
1 hr 64(+4) 46(—14) 
1.5 hr 49(—11) 48(—12) 
2 hr 56(4) 46(-14) 
4 hr 40(-20) 44(-16) 
6 hr 56(-4) 56(—4) 
8 hr 56(-4) 56(-6) 
Greatest 
Absolute 
Change /20/ /16/ 
SUBJECTS 
3 4 5 
60 50 60 
64 (+4) 64(+14) 72(+12) 
64(+4) 52(+2) 68(+8) 
58(-2) 56(+6) 61(+1) 
58(-2) 56(+6) 60(0) 
60(0) 60(+10) 60(0) 
56(—4) 60 (+10) 60(0) 
56(-4) 64 (+14) 68(+8) 
60(0) 62 (+2) 62(+2) 
/ 4/ /i4/ m i 
6 7 8 
80 60 72 
86 (+6) 60(0) 68(-4) 
68 (-12) 64(+4) 68(—4) 
68(-12) 64(+4) 68(-4) 
66(-14) 60(0) 64 (-8) 
62(-18) 60(0) 64(-8) 
62(-18) 60(0) 84 (+12) 
64C-16) 72(+12) 64(-8) 
68(-12) 60(0) 76(+4) 
718/ 712/ /12/ 
Mean greatest absolute change = 13 ± 5 
(does not include Subject 6) 
+Beats per minute 
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TABLE 9. RECORDED PULSE (AMD CHANGES FROM BASELINE) 
FOR ELDERLY SUBJECTS 
TIME SUBJECTS 
£ 10 li 11 13 14 16 17 
Baseline 74 76 84 68 64 76 60 68 
0.25 hr 66(-8) 72(-4) 84(0) - 68(+4) 68(-8) 76(+16) 46(-22) 
0.50 hr 62(-12) 76(0) 84(0) 72(+4) 68(+4) 66(—10) 84 (+24) 74(+6) 
1 hr 64(-10) 76(0) 80(-4) 56(-12) 64(0) 62(-14) 68(+8) 68(0) 
1.5 hr 62(-12) 72(-4) 86(+2) 54(—14) 60(-4) 64(-12) 78(+18) 70 (+2) 
2 hr 60(-14) 60(-16) 80(-4) 60(-8) 62(-2) 68(-8) 60(0) 72 (+4) 
4 hr 62(-12) 64(-12) 84(0) 64(-4) 66(+2) 68(-8) 60(0) 84(+16) 
6 hr 66(-8) 72(-4) 80(-4) 84(+16) 62(-2) 62(-14) 80(+20) 86(+18) 
8 hr 70(-4) 68(—8) 80(-4) 76(+8) 64(0) 66(-10) 72(+12) 88(+20) 
Greatest 
Absolute 
Change /14/ 716/ /4/ /16/ /4/ /14/ /24/ /22/ 
Mean greatest absolute change = 13 ± 6 
(does not Include Subject 17) 
+Beats per minute 
TABLE 10. RECORDED BLOOD 
TIME 
1 1 1 
Baseline 110/64 128/80 110/70 
0.25 hr 122/78 134/84 124/64 
0.5 hr 124/78 124/90 126/60 
1 hr 112/66 122/86 120/54 
1.5 hr 114/74 124/80 123/68 
2 hr 120/78 122/80 120/58 
4 hr 120/60 120/92 120/70 
6 hr 118/74 130/88 120/68 
8 hr 116/82 120/80 122/78 
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PRESSURE FOR YOUNG SUBJECTS* 
SUBJECT 
4 5 6 7 8 
120/80 130/80 130/86 130/80 134/78 
110/90 130/76 120/70 128/88 128/80 
114/90 120/68 112/66 134/88 122/74 
120/84 110/60 110/70 150/90 138/82 
120/84 100/60 114/74 150/90 112/72 
120/80 102/60 106/68 140/84 110/72 
120/80 110/60 120/70 120/84 126/88 
120/88 124/74 120/76 138/84 118/76 




TABLE 11. RECORDED BLOOD PRESSURE FOR ELDERLY SUBJECTS* 
TIME SUBJECT 
i i i i i i l i i i i l i i Z 
Baseline 146/88 120/70 134/70 138/90 152/96 122/68 164/86 182/90 
0.25 hr 138/80 138/72 142/78 - 152/88 112/60 180/90 174/88 
0.5 hr 140/90 144/78 138/74 136/88 158/96 118/70 174/88 180/80 
1 hr 140/90 144/78 138/74 136/88 158/96 118/70 152/76 168/66 
1.5 hr 140/84 132/72 132/78 140/84 146/88 112/66 152/84 146/80 
2 hr 140/88 114/68 128/76 134/80 142/84 112/70 144/76 138/72 
4 hr 136/90 110/70 132/86 140/86 142/88 110/62 154/82 130/78 
6 hr 138/92 118/60 110/70 148/98 134/78 110/62 134/70 142/72 




TABLE 12. RECORDINGS OF THE SEDATION SCALE FOR YOUNG SUBJECTS 
TIME SUBJECT 
, 1 2 3 4 5 6 7 8 
Baseline 0 0 0 0 0 0 0 0 
0.25 hr 2 1 1 1 1 1 1 1 
0.5 hr 2 1 1 1 1 1 3 1 
1 hr 2 2 1 1 0 1 3 1 
1.5 hr 3 2 1 1 0 1 3 1 
2 hr 2 1 2 2 0 0 3 1 
4 hr 0 0 0 0 0 0 1 0 
6 hr 0 0 0 0 0 0 0 0 
8 hr 0 0 0 0 0 0 0 0 
TABLE 13. RECORDINGS OE THE SEDATION SCALE FOR ELDERLY SUBJECTS 
TIME SUBJECT 
9 ID 11 12 13 14 16 
Baseline 0 0 0 0 0 0 0 
0.25 hr 1 1 0 - 1 2 1 
0.5 hr 1 2 1 1 1 2 1 
1 hr 1 2 1 2 1 2 2 
1.5 hr 1 2 1 2 - 1 2 
2 hr 1 1 1 2 1 
4 hr 0 1 1 - 0 0 0 
6 hr 0 0 0 0 0 0 0 
8 hr 0 0 0 0 0 0 0 
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TABLE 14. MEAN DEGREE, TIME OF ONSET AND DURATION OF GREATEST 
SEDATION FOR YOUNG AND ELDERLY SUBJECTS 
Young Elderly 
Degree of Sedation 2 + 1 2 ± 1 
Time of Onset (hrs) 1.1 ± 0.8 0.5 ± 0.3 
Duration (hrs) 0.61 ± 0.8 1.39 ± 1.0 
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TABLE 15. ADVERSE EFFECTS EXPERIENCED BY EACH SUBJECT 
SUBJECT ADVERSE EFFECT 
1 Numb feeling at 30 minutes, diaphoresis 
2 Lightheadedness, visual changes, dizziness, 
poor concentration 
3 Tingling 
4 Dry mouth 
5 No adverse effect 
6 Flushing, diaphoresis 
7 Euphoria, visual changes, headache, dry mouth 
8 Euphoria, slurred speech, dry mouth, itching, 
diaphoresis 
9 Diaphoresis, dry mouth, itching 
10 No adverse effects 
11 Itching 
12 Apnea, dizziness, headache 
13 Tingling, headache, nausea and vomiting, 
diaphoresis, dry mouth 
14 Feeling as if he had to force himself to breathe 
16 Slurred speech, dizziness 
17 Nausea and vomiting 
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TABLE 16. COMMON ADVERSE EFFECTS EXPERIENCED BY YOUNG AND ELDERLY 
SUBJECTS FOLLOWING ADMINISTRATION OF BUTORPHANOL 
ADVERSE EFFECT NUMBER OF SUBJECTS EXPERIENCING ADVERSE 
EFFECT (1=14) 









FIGURE 1. SERUM BUTORPHANOL CONCENTRATION VERSUS 
CHANGES IN RESPIRATORY RATE 
-15 -10 -5 0 5 10 
Changes in respiratory rate (from baseline) 
r = -0.159 
p - 0.248 
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THE INFLUENCE OF AGE ON THE PHARMACOKINETICS OF BUTORPHANOL (SIADOL®) 
Subject Consent Form 
The purpose of this research study is^ to compare how rapidly the 
body removes butorphanol tartrate (Stadol ) in elderly versus young 
human male volunteers. To accomplish this objective, you will be 
given a single dose of the drug injected into your veins, followed by 
a twenty-four hour period of observation and data collection. 
Butorphanol is used to relieve moderate to severe pain, such as that 
associated with cancer and various surgical procedures. 
In order to determine your eligibility for participation, a 
medical evaluation will be performed. This will include a comp 1 e t e 
physical examination as well as medical and medication histories. In 
addition, 15 milliliters (approximately 3 teaspoonfuls) of blood will 
be obtained by venipuncture (inserting a needle into a vein) and a 
urine sample will be collected in order to perform the necessary 
laboratory tests. An electrocardiogram (an electrical mapping of 
your heart) will also be obtained. 
If the initial evaluation indicates that you are a suitable 
candidate for participation, you will be scheduled to come in to the 
University Hospital Clinical Research Center to receive a single two 
milligram dose of Butorphanol tartrate. A ten milliliter (approxi-
mately two teaspoonfuls) blood sample will be obtained prior to the 
administration of the drug. At regularly scheduled times over the 
following twenty-four hour period either 5 or 10 milliliters of blood 
will be obtained. A total of fourteen blood samples will be drawn 
(totaling approximately 6 tablespoonfuls) from an indwelling venous 
CO. til 6 tlS 3T { a needle temporarily placed in a vein to obtain blood 
samples) . A total of approximately seven (7) tablespoonfuls of blood 
will be taken from your body for the study. 
In addition, you will be observed for any subjective changes 
such as drowsiness or sleepiness following the administration of the 
drug by recording your blood pressure, pulse, respiratory rate and 
degree of sedation. During the first two hours of the study you will 
be asked to remain in bed, after which time a wider range of activity 
will be permitted within the study unit. 
In order to obtain valid results, you will be asked to avoid 
eating any food for twelve hours prior to and for four hours after 
receiving the drug. During this period, water will be made available 
to you as you desire. A meal will be provided to you in four hours 
after the drug is administered and you will be able to resume your 
normal eating habits eight hours after the drug is administered. You 
will also be asked to refrain from smoking any substance or drinking 
alcoholic beverages for one week prior to and during the study. 
Butorphanol tartrate has been used clinically for several years 
in the United States and is approved by the Food and Drug Adminis-
tration. The most common side effects experienced are sedation, 
nausea, dizziness, confusion, headache, sweating and possibly slowing 
of breathing. These resolve with discontinuation of the drug and are 
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generally not considered serious conditions in the dose that will be 
administered to you. In the unlikely event that excessive sedation 
or breathing difficulty do occur, you will be given naloxone, an 
antidote for buthorphanol, at the direction of the physician investi-
gator. This antidote will be injected into your veins. At that 
point, your participation in this study will be terminated. If you 
develop severe nausea or vomiting during the investigation, you will 
be given a drug known as droperidol, injected into your veins. 
Droperidol is used by doctors to relieve some of the discomfort and 
feelings of nausea and vomiting. 
The risks from participating in this study include the possibil-
ity of side effects from butorphanol as described above. In 
addition, blood sampling may be slightly painful and may cause 
temporary bruising or inflammation at the site of needle insertion. 
Although you may not directly benefit medically from partici-
pating, it is hoped that the results obtained will aid in furthering 
rational therapy for pain in the geriatric population. However, 
because of the pain, discomfort and inconvenience that you may endure 
as a result of your participation, you will be reimbursed $150 for 
successfully completing this study. In the event you do not complete 
the entire study, you will be reimbursed commensurate with the time 
spent in the study. Additional benefits will include a complete 
physical examination, electrocardiogram and laboratory tests free of 
charge (used to determine your eligibility for this study), 
lour participation is completely voluntary and you may be 
withdrawn at any time either by your decision or by that of the 
investigator. This will not result in any penalty or loss of bene-
fits to which you are otherwise entitled. 
The data obtained from this study will be ^ d for the advance^  
ment of medical and scientific knowledge, and as such may be 
considered for publication. In a d d i t i o n - " V ™ ? ™ ™ ^ 9 ^ 
Laboratories and the Food and Drug Administrat^ 
records collected during this investigation. All information obtain 
ed will remain confidential. 
In the event you sustain physical injury resulting 
.-•iJr-in 1-h-Ifi research project, the University of Utah will provide pation in this research proje t, a r y medical treatment not you, free of charge emergency and temp e m o r e > i f your 
otherwise covered by ^dic^ insuranc Q f U n i v e r s i t y 
injuries are c.se by ^ f l u d scope of their employment the 
employees acting in the course a F i t A t i a n B prescribed by law, 
University may be liable, subject to SUBtain. If you for additional medical costs and other damages y r e s u i t o f 
believe that you have suffered a• ^ ^ ^ ^ t h e office of 
participation in this " s e a r c h program, plea" con 
research administration, telephone number (801) 581 
,. „ t u d v nav be asked at any time and 
Questions regarding t*is study { 8 0 1_ 5 8 1_ 6 239) or Dr. 
should be directed to Dr. Martin^ ^ ^ ^ n u m b e r s > 
Ruthanne Ramsey (801-581-tuu<u . 
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questions regarding the study may be asked 24 hours a day by calling 
(801) 521-1221 and asking the operator for beeper #158, or by calling 
(801) 943-1939. If you have questions that you do not wish to 
discuss with the investigator, you may contact the investigational 
review board at (801) 581-3655. 
I, , agree to partici-
pate in this research study which is entitled "The Influence of Age 
on the Pharmacokinetics of Butorphanol". Upon signing this form, 1 
acknowledge that I have had the opportunity to ask questions about 
the procedures, risks, and other aspects that are involved in this 
investigation. I understand that I may withdraw my consent at any 
time without affecting the treatment I will receive. 
1 give my permission for the information gained in this study to 
be released to the investigators, Bristol Laboratories, and the Food 
and Drug Administration with the understanding that my identity will 
not be revealed unless I expressly consent thereto. By signing, I 
acknowledge that I have received a copy of this consent form. 
Subject Signature Date 
Witness Signature Date 
Investigator Signature Date 
APPENDIX B 
CASE REPORT FORM USED IN STUDY 
BRISTOL LABORATORIES 
MEDICAL DEPARTMENT 
P.O. BOX 4755 
SYRACUSE, NEW YORK 13221-4755 
THE INFLUENCE OF AGE 
ON THE 
PHARMACOKINETICS OF BUTORPHANOL (STADOL) 
Prlrdpol ln**»flgmjw (F'-wMm Prtwt) 
Martin Htgbee, Phomi.D. /Jomea Wood, M.P. 
Study Nurritxif 
300-098-001 
Subject Num6«r Subject InWais 
INSmUCmONS: 
Complete oil sections by  typing or writing legibly in block Ink only. 
Aft®? reviewing the comoleied coae naooft term and checking H for comtHetenese 
and occurccv, the onneioai invest) got or Tiusi sifijn the report end return H to the 
Cfinlcol Reseorcn Aawseicte at the ooove oddnwe. 
FOR BRfSTOL USE  ONLY: 
Dote Received , 




P.O. BOX 4755 
SYRACUSE. N.Y. 
13221-4755 
CLINICAL CASE REPORT 
BUTORPHANOL Study Numo«r 
3C0—068—001 
Si*2ect HisnDer I Sobfset mtioli 
y« No 
a a Does the subject hov» a history of drug or alcohol obuse? 
p a Dee* ths subject hov» o history of opiate tolerance or dependwice? 
• • Does the subject haw decompensated cofta#st»« heort failure? 
• • Does the subject have o history of cplote hyp«rssn»ISviky? 
o • Is the subject femoie? 
• • Is the potient outside at the oge groups; 20-+0 or 60-93 years? 
• 0 le the luliject allergic ts butorphanol 
• 0 Does the subject have chronic obstructive lung diaeose? 
• • • Are ortf chronic medications likely to be needed during the study? 
• 0 le the subject 253 above or below th«!r Ideal body weight? 
• D Hoe the subject smoked during the week prior to the study? 
• 0 Has the subject consumed alcohol during the week prior to the study? 
• 0 Dom the eubjeet have abnomial laborofaxy Indices tor their age gmup? 
H  Yea (a cheeked for  any cf tho ofcove, tfie patierrt Is Ineligible end should not 
be enrolled in this study. 
a D Has the subject fasted for 12 tiaura? 
a 0 Has ttie subject signed an Informed «ns«nt ajre«nent? 
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BRISTOL LABORATORIES 
P.O. BOX 4755 
SYRACUSE. N.Y. 
13221-4755 
CUNICAL CASE REPORT 
BUTORPHANOL SNumt*r 300—098—001 
Subject NsfflMr I Subfeet urta* 
mmmmmmmm  < SU^t ^R^ ON m^mmmmmM Siitjfaci Initials (rlrat—Mlddl«—itist) pat* of 9Kh (Mo.-0ay-rr.3 A9» • M S . O Yr. SAX OMola (U) a Femol i (F) 
Hoc® 
O Whits 
O Black • Othor (Sp«clfy): 
Height fl In 
Q em 
W«i§hl o lb 
• kq 
Hoaprtol/Institution Locution (City oiM Stolo) 
' inn i nmnl •iiimi IIII'I ' '"i iii'nTTr" " ' "** 1 ' ™ 1 • — ' •• "" _'*pl . mu " 1 " " -" ' • " j ^ T ^ ' " — n i —W n , "" in 
^ K ^ r i j A - ^ ^ S f f g ^  2 PHYSICAL EXAMINATION A N D MEDICAL H ISTORY 
DATE OF EVALUATION (Mo/Doy /Yr ) : 
Phas9 mom any ctn&rmaJ/t'as  en physical examination and medket history. 
If ofcmprraoj, complete tha following; 
Physical £xam Mefitcci History Dermoteiaoic 












Does the subject have o history of: Yes No • • AJIergiem: O dmg • food • other 
• • SrnoWng: Number of  peek yeem 
P • Chronic use of ony medieoUon? Specify 
Specify 
V-tf  3 SUJDY MEDICATION K-^ xcy^ x';;;: 
Siodol Ooae»2fng fV Lot > iumeer 
OoU Time Comments j J 
Insertion of W 1 ' BuEornhonol Administration 1 1 
Other Cruos . 1 (Home / Dose) ; 
i 1 . 
i 
BRISTOL LABORATORIES 
P.O. BOX 4755 CLINICAL CASE REPORT Study Numotr 
SYRACUSE, N.Y. BUTORPHANOL 3Q0 - 093 -001 
13221-4755 HutNfr M>|«C InltMa 
3 4 BLOOD SAMPLING 

























Bhtxi should ba centrifugea  and plasma it wiOttSmm end frozen  within 
Volume of blood sample - 5mt 
1 hour 0/  blood sampling. 
Date of sampling: 
Mo/Doy/Yr 
Data samples sent to lab: 
Date blood 
Mo/0ey/Vf 
concentrations received from  tats: 
Mo/Doy/Yr 
Pharmacokinetic Parameters 
T : HaMIife: Alpha Beta 
V.: AUC: . CllflPjnw 
- 51 S i) 
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BRISTOL LABORATORIES 
1 P.O. BOX 4755 CLINICAL CASE REPORT Stud* HumMi* 
1 SYRACUSE. N.Y. BUTORPHANOL 300 —098—001 
1 
13221-4755 Subjaet Nuwb* Subject initial* 


















Scselin® / | 
j j 
15 min. / 1 | 1 
j | 
3D min. / 1 | 1 
! I 
i hr. ' 1 1 
i ! 1 
1.5 hr. / i j 
1 i 
2 hr. / 1 1 i 
| | j 
4 hr. / | | 1 
8 hr. / 1 1 1 
1 1 
8 hr. / 1 i 1 
| I j 
12 hr. ' / I I i i 
I I 1 ! ! 1 
hr. 1 / ! ' 1 i 
1 1 i 1 




P.O. BOX 4755 CLINICAL CASE REPORT Study Ku*n6«r 
SYRACUSE, N.Y. BUTORPHANOL 300 -098—001 
13221 -4755 Subjoet HumMr Subject initiate 
6 ADVERSE EXPERIENCES 





NoU: If question 2 below la answered Yes, b« sura 
to record any Uieraoy in thi appr&pricta auction 
of Iftia CRF. 
O Hrs 
• Ooya 
Imb (ortd «ttM) csnAttnutg nwetkMi: 
»t, CwtcMM of rMCtiMi la bet* (inMrt uxM> from t**Wh , ,. ....••„ 
la) W«* lTMint*nl f«»wM) • Ym • Mo &} • Outset}** • H«aotUW<M 
X Wh mtuOf  r»fl«c*l  in  t**t?  • Xt»  • Hi or Q  Oilcan tint** 
tf m> reaction «tMt«? Q Y*a • No 
4,o) Wan iOi9|> flruq r*mc«4ue*<s? • Y«* Qti* 
b) Did reaction rwsoevcr? • TM Q JN« 
a Hm 
D Days 
Lab EhU (end ckrtaa) rvocsoru 
•I, Qutcoma art fMcfisn la dot* (Iflia* eoea tnm 
2.0) Woa fcr»«tm**t rmsum<7  O Y«a O Ko b) O OutpaOofrt Q»*Q*CHtBix«l 
X Was * turfy mducwi in «»•? G Y*i • Ns Q CiK-oninuari 
If IB. did race on a«at«? • Ym • Ho 
4.A) WAI »a>FFY ormj i*»!rwiuc*al Q T<MI Q HA 
fa) Old rwaction mapp**T!  • Y«t 0 Ho 
a Hf3 • Days 
Lob tMM (end cannrmi^  nwcaofl; 
•!, CMs»m» rwrftian  (9<»ui {ln*m from •• • 
2jt) We* traaSmwu requires? 0 Yin • Hs b) • CutEttdett OHaawtOJlMHl 
Wat «tuay druq neu£*4 do»*t Q Y«* Q No or • 
If Mi aid roaccon oecl»? Q r«« Q No 
4,a} Wat aQM^r dry* r*in«nHJu<»«? O Y*» 0 
b> CM nwttiBn roeppttrt • Q Ho 
•OUTCOME CODES: 1. Aiive with sequelae 
2. Recovered 
3. SUil under t/eotment for reaction 
4. Died (givft couao and dote under 1, obovo) 
Comments; Describe meo/ea/  history  reteront  to the above stated  experiences (i.e. energies,  environmental 





0 None, awake fully 
1 Drowsy, sleepy but responsive to 
various background stimuli 
2 Somnolent, appears asleep but responds 
to direct verbal commands 
3 Asleep 
"^ Developed by Bristol Laboratories 
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CALCULATION AND DEFINITION OF PHARMACOKINETIC PARAMETERS 
The following is a brief presentation of the equations used to drive 
the pharmacokinetic parameters discussed in this paper. 
1) AUG = area under the curve to infinity. 
This is an estimation of the area under a semilog plot of drug 
concentration versus time to infinity. This value was obtained 
by the relationship: 
n 
^i/Xi' w ^ e r e C = coefficient and X = exponent 
i 
used to describe the pharmacokinetic model. 
2) AUMC - area under the (first) moment curve to infinity. This is 
the area under a plot of the product of concentration and time 
versus time from zero time to infinity. This value was calcu-
lated according to the relationship: 
n ^ 
EC,/(X.) ; where C = coefficient and A = exponent 
i 1 1 
used to describe the pharmacokinetic model. 
3) Vd = the apparent steady state volume of distribution, s s 
This value is obtained by the relationship 
Vd - dose (AUMC)/(AUG)2 
4) Cl = total body clearance 
tot J CL^  = Dose_,,/AUC tot IV 
5) T, = terminal elimination half-life. The terminal elimination 
half-life was calculated from the logarithmic plot of the serum 
concentration versus time for each individual. The terminal 
slope of the line was the elimination rate constant (K^) and 
the half-life (t,) was determined by the relationship t, = 
0.693/k ! 
APPENDIX E 
Individual Values of Serum Butorphanol Concentrations 
Obtained During the Data Collection Phase 
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BUTORPHANOL SERUM DRUG CONCENTRATIONS 
Subject Number 1 Time of Drug Administration 0 5 
Sample Number Actual Time Drawn Serum Drug Concentration (ng/ml) 
01 (baseline) 0835 < 0.03 
02 (2 min) 0837 14.5 
03 (5 min) 0840 10,0 
04 (10 min) 0845 8.40 
05 (15 min) 0850 5.0 
06 (30 min) 0905 2.75 
07 (45 min) 0920 2.20 
08 (1 hour) 0935 1.75 
09 (1.5 hour) 1005 1.35 
10 (2 hours) 1035 1.10 
11 (4 hours) 1235 1.15 
12 (6 hours) 1435 0.58 
13 (8 hours) 1635 0.50 
14 (12 hours) 2035 0.19 
15 (24 hours) 0835 0.09 
BUTORPHANOL SERUM DRUG CONCENTRATIONS 
Subject Number 2 Time of Drug Administration 07 
Sample Number Actual Time Drawn Serum Drug Concentration (ng/ml) 
01 (baseline) 0746 < 0.03 
02 (2 min) 0748 8.60 
03 (5 min) 0751 6.60 
04 (10 min) 0756 5.20 
05 (15 min) 0801 3.20 
06 (30 min) 0816 2.80 
07 (45 min) 0831 1.90 
08 (1 hour) 0846 2.05 
09 (1.5 hour) 0916 1.70 
10 (2 hours) 0946 1.45 
11 (4 hours) 1146 1.25 
12 (6 hours) 1346 0.50 
13 (8 hours) 1546 0.35 
14 (12 hours) 1946 0.16 
15 (24 hours) 0746 0.03 
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BUTORPHANOL SERUM DRUG CONCENTRATIONS 
Subject Number Time of Drug Administration 0 
Sample Number Actual Time Drawn Serum Drug Concentration (ng/ml) 
01 (baseline) 0725 < 0.03 
02 (2 min) 0732 7.00 
03 (5 min) 0735 6.00 
04 (10 min) 0740 4.80 
05 (15 min) 0745 4.00 
06 (30 min) 0800 3.00 
07 (45 min) 0815 2.50 
08 (1 hour) 0830 2.10 
09 (1.5 hour) 0900 2.00 
10 (2 hours) 0930 1.70 
11 (4 hours) 1130 1.25 
12 (6 hours) 1330 0.72 
13 (8 hours) 1530 0.45 
14 (12 hours) 1930 0.34 
15 (24 hours) 0730 0,05 
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BUTORPHANOL SERUM DRUG CONCENTRATIONS 
Subject Number 4 Time of Drug Administration 0 5 
Sample Number Actual Time Drawn Serum Drug Concentration (ng/ml) 
_ J —• i i i ..—Hi.. .—ii ii.i. • i — i 
01 (baseline) 0721 < 0.03 
02 (2 min) 0727 14.80 
03 (5 min) 0730 6.00 
04 (10 min) 0735 3.90 
05 (15 min) 0740 2.40 
06 (30 min) 0755 2.20 
07 (45 min) 0810 1.60 
08 (1 hour) 0825 1.40 
09 (1.5 hour) 0855 1.30 
10 (2 hours) 0925 1.10 
11 (4 hours) 1125 1.05 
12 (6 hours) 1335 0.63 
13 (8 hours) 1525 0.42 
14 (12 hours) 1925 0.26 
15 (24 hours) 0725 0.05 
BUTORPHANOL SERUM DRUG CONCENTRATIONS 
Subject Number Time of Drug Administration 070 
Sample Number Actual Time Drawn Serum Drug Concentration (ng/ml) 
01 (baseline) 0730 < 0.03 
02 (2 min) 0742 8.05 
03 (5 min) 0745 3.80 
04 (10 min) 0750 2.90 
05 (15 min) 0755 2.40 
06 (30 min) 0810 1.45 
07 (45 min) 0825 1.25 
08 (1 hour) 0840 1.10 
09 (1.5 hour) 0910 0.79 
10 (2 hours) 0940 0.83 
11 (4 hours) 1140 0.68 
12 (6 hours) 1340 0.44 
13 (8 hours) 1540 0.28 
14 (12 hours) 1940 0.21 
15 (24 hours) 0740 0.07 
BUTORPHANOL SERUM DRUG CONCENTRATIONS 
Subject Number 7 Time of Drug Administration 0710 
Sample Number Actual Time Drawn Serum Drug Concentrat 
01 (baseline) 0700 < 0,03 
02 (2 min) 0713 4.60 
03 (5 min) 0715 4.40 
04 (10 min) 0720 2.80 
05 (15 min) 0725 3.00 
06 (30 min) 0740 1.90 
07 (45 min) 0800 1.50 
08 (1 hour) 0810 1.40 
09 (1.5 hour) 0840 1.40 
10 (2 hours) 0910 1.25 
11 (4 hours) 1110 0.68 
12 (6 hours) 1310 0.56 
13 (8 hours) 1510 0.39 
14 (12 hours) 1910 0.18 
15 (24 hours) 0710 0.06 
74 
BUTORPHANOL SERUM DRUG CONCENTRATIONS 
Subject Number Time of Drug Administration 0 
Sample Number Actual Time Drawn Serum Drug Concentration (ng/ml) 
01 (baseline) 0735 < 0.03 
02 (2 min) 0743 4.40 
03 (5 min) 0745 3.75 
04 (10 min) 0750 2 • 85 
05 (15 min) 0755 2.20 
06 (30 min) 0810 1.70 
07 (45 min) 0825 1.35 
08 (1 hour) 0840 1.35 
09 (1.5 hour) 0910 1 • 2 3 
10 (2 hours) 0940 1.10 
11 (4 hours) 1140 0.65 
12 (6 hours) 1340 0.40 
13 (8 hours) 1540 0.28 
14 (12 hours) 1940 0.17 
15 (24 hours) 0740 0.03 
BUTORPHANOL SERUM DRUG CONCENTRATIONS 
Subject Number Time of Drug Administration 073 
Sample Number Actual Time Drawn Serum Drug Concentration (ng/ml) 
01 (baseline) 0735 < 0.03 
02 (2 min) 0741 17.50 
03 (5 min) 0744 5.00 
04 (10 min) 0749 4.00 
05 (15 min) 0754 3.40 
06 (30 min) 0809 1.95 
07 (45 min) 0824 1.75 
08 (1 hour) 0839 1.35 
09 (1.5 hour) 0909 1.20 
10 (2 hours) 0939 l.OO 
11 (4 hours) 1139 0.78 
12 (6 hours) 1339 0.54 
13 (8 hours) 1540 0.40 
14 (12 hours) 1939 0.28 
15 (24 hours) 0739 0.13 
76 
BUTORPHANOL SERUM DRUG CONCENTRATIONS 
Subject Number 1 Time of Drug Administration 0 
Sample Number Actual Time Drawn Serum Drug Concentration (ng/ml) 
01 (baseline) 0657 < 0.03 
02 (2 min) 0702 24.80 
03 (5 min) 0705 5.40 
04 (10 min) 0710 3.90 
05 (15 min) 0715 3 * 25 
06 (30 min) 0730 2.40 
07 (45 min) 0745 1.75 
08 (1 hour) 0800 1.50 
09 (1.5 hour) 0830 1.10 
10 (2 hours) 0900 1.00 
11 (4 hours) 1100 0.72 
12 (6 hours) 1300 0.52 
13 (8 hours) 1500 0.40 
14 (12 hours) 1900 0.28 
15 (24 hours) 0700 0.08 
77 
BUTORPHANOL SERUM DRUG CONCENTRATIONS 
Subject Number 1 Time of Drug Administration 0 5 
Sample Number Actual Time Drawn Serum Drug Concentration (ng/ml) 
01 (baseline) 0708 < 0.03 
02 (2 min) 0718 7.20 
03 (5 min) 0720 5.00 
04 (10 min) 0725 3.50 
05 (15 min) 0730 3.00 
06 (30 min) 0745 2.40 
07 (45 min) 0800 2.00 
08 (1 hour) 0815 1.90 
09 (1.5 hour) 0845 1.45 
10 (2 hours) 0915 1.20 
11 (4 hours) 1115 1.10 
12 (6 hours) 1315 0.88 
13 (8 hours) 1515 0.78 
14 (12 hours) 1915 0.66 
15 (24 hours) 0715 0.54 
BUTORPHANOL SERUM DRUG CONCENTRATIONS 
Subject Number 12 Time of Drug Administration 0730 
Sample Number Actual Time Drawn Serum Drug Concentration (ng/ml) 
01 (baseline) 0727 QNS 
02 (2 min) 0732 24.00 
03 (5 min) 0735 5.60 
04 (10 min) 0740 4.40 
05 (15 min) 0745 QNS 
06 (30 min) 0800 1.85 
07 (45 min) 0815 1.60 
08 (1 hour) 0830 1.25 
09 (1.5 hour) 0900 1.10 
10 (2 hours) 0930 0.95 
11 (4 hours) 1130 0.58 
12 (6 hours) 1330 0.50 
13 (8 hours) 1530 0.28 
14 (12 hours) 1930 0.11 
15 (24 hours) 0730 0.03 
BUTORPHANOL SERUM DRUG CONCENTRATIONS 
Subject Number 13 Time of Drug Administration 0820 
Sample Number Actual Time Drawn Serum Drug Concentration (ng/ml) 
01 (baseline) 0817 < 0.03 
02 (2 min) 0824 13.10 
03 (5 min) 0825 8.80 
04 (10 min) 0830 5.00 
05 (15 min) 0835 4.00 
06 (30 min) 0850 2.50 
07 (45 min) 0905 2.30 
08 (1 hour) 0920 1.80 
09 (1.5 hour) 0950 1.45 
10 (2 hours) 1020 1.25 
11 (4 hours) 1220 0.70 
12 (6 hours) 1420 0,51 
13 (8 hours) 1620 0.44 
14 (12 hours) 2020 0.20 
15 (24 hours) 0735 0.09 
80 
BUTORPHANOL SERUM DRUG CONCENTRATIONS 
Subject Number 14 Time of Drug Administration 0655 
Sample Number Actual Time Drawn Serum Drug Concentration (ng/ml) 
01 (baseline) 0653 <0.03 
02 (2 min) 0657 1.50 
03 (5 min) 0701 6.20 
04 (10 min) 0705 5.20 
05 (15 min) 0710 3.50 
06 (30 min) 0725 2.20 
0? (45 min) 0740 2.00 
08 (1 hour) 0755 1.60 
09 (1.5 hour) 0825 1.20 
10 (2 hours) 0855 1.10 
11 (4 hours) 1055 0.78 
12 (6 hours) 1255 0.44 
13 (8 hours) 1455 0.28 
14 (12 hours) 1855 0.16 
15 (24 hours) 0655 0.08 
BUTORPHANOL SERUM DRUG CONCENTRATIONS 
Subject Number Time of Drug Administration 0730 
Sample Number Actual Time Drawn Serum Drug Concentration (ng/ml) 
01 (baseline) 0722 < 0.03 
02 (2 min) 0732 22.50 
03 (5 min) 0735 6.30 
04 (10 min) 0740 5.60 
05 (15 min) 0745 4.40 
06 (30 min) 0800 2.40 
07 (45 min) 0815 1.75 
08 (1 hour) 0830 1.60 
09 (1.5 hour) 0900 1.10 
10 (2 hours) 0930 1.10 
11 (4 hours) 1130 0.65 
12 (6 hours) 1330 0,46 
13 (8 hours) 1530 0.42 
14 (12 hours) 1930 0.27 
15 (24 hours) 0730 0.11 
APPENDIX P 
Computer Generated Non-Linear Regression Analysis Plots of 
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